These are publications from work undertaken by Frontier Science (Scotland).

1 2 3 4 5 6
D Eiger;  N F Pondé; D Agbor-Tarh; A Moreno-Aspitia; M. Piccart; F Hilbers; O Werner; S Chumsri; A Dueck; J R Kroep; H Gomez; I Láng; R J Rodeheffer; M S Ewer; T Suter; E. de Azambuja;  16 March 2020

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial

British Journal of Cancer,  Volume 122, pp 1453–1460(2020), doi:10.1038/s41416-020-0786-x

M Procter;  T M Suter; E. de Azambuja; U Dafni; V Van Dooren; S Muehlbauer; M Angel Climent; E Rechberger; W Tsang-Wu Liu; M Toi; R C Coombes; D Dodwell; O Pagani; J Madrid; M Hall; S Chen; C Focan; M Muscholl; D J van Veldhuisen; M Piccart-Gebhart;  2010

Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial

Journal of Clinical Oncology,  Volume 28 (21) pp 3422-3428, 10.1200/JCO.2009.26.0463

E McFadden;  J Jackson; J Forrest;  2019

Documentation: Essential Documents and Standard Operating Procedures

Principles and Practice of Clinical Trials,  Published online 8 November 2019, doi:10.1007/978-3-319-52677-5_45-1

J Bines;  M Procter; E Restuccia; G Viale; D Zardavas; T Suter; A Arahmani; V Van Dooren; J Baselga; E Clark; J Eng-Wong; RD Gelber; M. Piccart; V Mobus; E. de Azambuja;  2019

Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-positive breast cancer patients

Clinical Breast Cancer,  Pages 174 - 181, Volume 20 Issue 2. Published online 5 September 2019, doi:10.1016/j.clbc.2019.06.016

R Hui;  A Pearson; J Cortés; C Campbell; C Poirot; H A Azim; D Fumagalli; M Lambertini; F Daly; A Arahmani; J Pérez-Garcia; P Aftimos; P L Bedard; L Xuereb; E D Scheepers; M Vicente; T Goulioti; S Loibl; S Loi; M-J Pierrat; N C Turner; F Andre; G Curigliano;  2020

Lucitanib for the treatment of HR+/ HER2- metastatic breast cancer: results from the multicohort phase II FINESSE study

Clinical Cancer Research,  Volume 26(2), pp 354-363, doi:10.1158/1078-0432.CCR-19-1164

E. de Azambuja;  N Ponde; M Procter; P Rastogi; R S Cecchini; M Lambertini; K Ballman; A Moreno-Aspitia; D Zardavas; L Roca; RD Gelber; M Piccart-Gebhart; T Suter;  11 October 2019

A Pooled Analysis of the Cardiac Events in the Trastuzumab Adjuvant Trials

Breast Cancer Research and Treatment,  11 October 2019, online first: doi:10.1007/s10549-019-05453-z

M Procter; 

Simulation Study to Estimate Bias of Treatment Effect in Pain Scores in Diabetic Neuropathy

Pain Medicine,  24 August 2019, online first: doi:10.1093/pm/pnz192

C Kersten;  M G Cameron; A G Bailey; M T Fallon; B J Laird; V Paterson; R Mitchell; S M Fleetwood-Walker; F Daly; S Mjåland;  20 May 2019

Relief of Neuropathic Pain Through Epidermal Growth Factor Receptor Inhibition: A Randomized Proof-of-Concept Trial

Pain Medicine,  20 May 2019, online first: doi:10.1093/pm/pnz101

J F R Robertson;  Z Jiang; A Di Leo; S Ohno; K I Pritchard; M Ellis; I Bradbury; C Campbell;  May 2019

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer

Breast Cancer,  11 May 2019, online first doi:10.1007/s12282-019-00973-4

W P Kirschbrown;  M Kågedal; B Wang; L Lindbom; A Knott; R Mack; S Monemi; I Nijem; S Girish; C Freeman; D Fumagalli; R McConnell; G Jerusalem; C Twelves; J Baselga; G von Minckwitz; J Bines; A Garg;  June 2019

Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

Cancer Chemotherapy and Pharmacology,  Volume 83, Issue No 6, pp. 1147-1158 doi:10.1007/s00280-019-03826-1

1 2 3 4 5 6